BRPI0818310A8 - Glicerídeos e ácidos graxos de cadeia média como agentes nefroprotetores - Google Patents
Glicerídeos e ácidos graxos de cadeia média como agentes nefroprotetoresInfo
- Publication number
- BRPI0818310A8 BRPI0818310A8 BRPI0818310A BRPI0818310A BRPI0818310A8 BR PI0818310 A8 BRPI0818310 A8 BR PI0818310A8 BR PI0818310 A BRPI0818310 A BR PI0818310A BR PI0818310 A BRPI0818310 A BR PI0818310A BR PI0818310 A8 BRPI0818310 A8 BR PI0818310A8
- Authority
- BR
- Brazil
- Prior art keywords
- fatty acids
- chain fatty
- medium chain
- glycerides
- agents
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 150000004667 medium chain fatty acids Chemical class 0.000 title abstract 3
- 230000001607 nephroprotective effect Effects 0.000 title abstract 3
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 abstract 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 239000005639 Lauric acid Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000013059 nephrectomy Methods 0.000 abstract 1
- 229960002446 octanoic acid Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98509407P | 2007-11-02 | 2007-11-02 | |
| PCT/CA2008/001930 WO2009055933A1 (en) | 2007-11-02 | 2008-11-03 | Medium-chain length fatty acids and glycerides as nephroprotection agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0818310A2 BRPI0818310A2 (pt) | 2017-10-10 |
| BRPI0818310A8 true BRPI0818310A8 (pt) | 2017-12-26 |
Family
ID=40590499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0818310A BRPI0818310A8 (pt) | 2007-11-02 | 2008-11-03 | Glicerídeos e ácidos graxos de cadeia média como agentes nefroprotetores |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9532962B2 (enExample) |
| EP (1) | EP2299998B1 (enExample) |
| JP (1) | JP5575655B2 (enExample) |
| KR (1) | KR101601987B1 (enExample) |
| CN (1) | CN101878028A (enExample) |
| AU (1) | AU2008318196B2 (enExample) |
| BR (1) | BRPI0818310A8 (enExample) |
| CA (1) | CA2704286C (enExample) |
| DK (1) | DK2299998T3 (enExample) |
| ES (1) | ES2664594T3 (enExample) |
| IL (1) | IL205362A (enExample) |
| MX (1) | MX338513B (enExample) |
| MY (1) | MY151439A (enExample) |
| NO (1) | NO2299998T3 (enExample) |
| NZ (1) | NZ584981A (enExample) |
| PT (1) | PT2299998T (enExample) |
| RU (1) | RU2519215C2 (enExample) |
| WO (1) | WO2009055933A1 (enExample) |
| ZA (1) | ZA201003030B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2427416T3 (pl) | 2009-05-04 | 2016-09-30 | Podstawione związki aromatyczne i ich zastosowania farmaceutyczne | |
| JP5706142B2 (ja) * | 2010-04-28 | 2015-04-22 | 株式会社ファンケル | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤 |
| TWI578983B (zh) * | 2010-10-27 | 2017-04-21 | 波麥堤克藥學Ｓｍｔ有限公司 | 用於治療癌症的化合物及組成物 |
| EP2749281B1 (en) * | 2011-08-26 | 2018-03-28 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
| KR20130023583A (ko) * | 2011-08-29 | 2013-03-08 | 아주대학교산학협력단 | 파골세포 형성 억제 효과가 있는 카프르산 및 이를 포함하는 약학적 조성물 |
| RU2016116835A (ru) | 2013-11-05 | 2017-12-11 | Хиллс Пет Нутришн, Инк. | Способы и композиции для улучшения функции почек |
| WO2017074266A1 (en) * | 2015-10-30 | 2017-05-04 | National University Of Singapore | Androgen biosynthesis inhibitor |
| CN105559071A (zh) * | 2016-01-12 | 2016-05-11 | 刘保惠 | 一种适用于肾病的特殊医学用途配方食品及其制备方法 |
| JP2017214342A (ja) * | 2016-06-02 | 2017-12-07 | 日清オイリオグループ株式会社 | 排尿障害の予防用又は改善用組成物 |
| NZ749389A (en) | 2016-06-08 | 2022-12-23 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| KR20190102011A (ko) * | 2016-12-21 | 2019-09-02 | 프로메틱 파마 에스엠티 리미티드 | 상피-중간엽 전이를 예방 또는 최소화하는 방법 및 조성물 |
| JP7055429B2 (ja) * | 2017-10-27 | 2022-04-18 | 学校法人北里研究所 | 慢性腎臓病の予防又は治療剤 |
| US20190240180A1 (en) * | 2018-02-08 | 2019-08-08 | Nestec Sa | Mct-based nutrition blend for providing health benefits in companion animals |
| EA202190890A1 (ru) | 2018-10-11 | 2021-09-10 | Басф Ас | Получение замещенных ароматических соединений и их применение в фармацевтике |
| CN109602012A (zh) * | 2018-12-11 | 2019-04-12 | 李卫平 | 一种功能性低蛋白能量米及其制备方法 |
| CN111184728B (zh) * | 2020-02-20 | 2023-04-04 | 上海市儿童医院 | 海藻糖在肾病综合征中的应用 |
| AU2023292465A1 (en) * | 2022-06-15 | 2024-12-12 | Hill's Pet Nutrition, Inc. | Pet food compositions |
| CN118592613B (zh) * | 2024-08-05 | 2025-01-07 | 杭州康源食品科技有限公司 | 中链脂肪酸混合结构脂在改善膳食诱导的糖脂代谢紊乱中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4602040A (en) | 1983-04-18 | 1986-07-22 | Warner-Lambert Company | Meclofenamic acid topical pharmaceutical composition |
| US4737384A (en) * | 1985-11-01 | 1988-04-12 | Allied Corporation | Deposition of thin films using supercritical fluids |
| CA2107581A1 (en) | 1992-02-07 | 1993-08-08 | Kiyoshi Sugiyama | Side-effect alleviant |
| US6689700B1 (en) * | 1999-11-02 | 2004-02-10 | University Of Massachusetts | Chemical fluid deposition method for the formation of metal and metal alloy films on patterned and unpatterned substrates |
| WO2001097799A1 (en) | 2000-06-20 | 2001-12-27 | Nutrition Sciences | Medium chain fatty acids applicable as antimicrobial agents |
| IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| PL222876B1 (pl) * | 2001-04-18 | 2016-09-30 | Prometic Biosciences Inc | Zastosowanie pochodnych glicerolu |
| CN1827766B (zh) | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
| RU2213570C2 (ru) * | 2001-08-22 | 2003-10-10 | Санкт-Петербургская Государственная Химико-Фармацевтическая Академия | ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ |
| US7030168B2 (en) * | 2001-12-31 | 2006-04-18 | Advanced Technology Materials, Inc. | Supercritical fluid-assisted deposition of materials on semiconductor substrates |
| US20040052836A1 (en) | 2002-09-13 | 2004-03-18 | Li Luk Chiu | Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life |
| NZ541593A (en) | 2003-02-07 | 2009-05-31 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis |
| PL1648851T3 (pl) | 2003-07-25 | 2007-09-28 | Prometic Biosciences Inc | Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami |
| EP1940379A4 (en) | 2005-09-30 | 2009-05-13 | Jackson H M Found Military Med | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |
-
2008
- 2008-11-03 AU AU2008318196A patent/AU2008318196B2/en not_active Ceased
- 2008-11-03 WO PCT/CA2008/001930 patent/WO2009055933A1/en not_active Ceased
- 2008-11-03 NO NO08845122A patent/NO2299998T3/no unknown
- 2008-11-03 MX MX2010004856A patent/MX338513B/es active IP Right Grant
- 2008-11-03 DK DK08845122.4T patent/DK2299998T3/en active
- 2008-11-03 NZ NZ584981A patent/NZ584981A/en not_active IP Right Cessation
- 2008-11-03 ES ES08845122.4T patent/ES2664594T3/es active Active
- 2008-11-03 CA CA2704286A patent/CA2704286C/en not_active Expired - Fee Related
- 2008-11-03 JP JP2010532389A patent/JP5575655B2/ja not_active Expired - Fee Related
- 2008-11-03 PT PT88451224T patent/PT2299998T/pt unknown
- 2008-11-03 US US12/740,700 patent/US9532962B2/en not_active Expired - Fee Related
- 2008-11-03 MY MYPI2010001861A patent/MY151439A/en unknown
- 2008-11-03 KR KR1020107012064A patent/KR101601987B1/ko not_active Expired - Fee Related
- 2008-11-03 RU RU2010122302/15A patent/RU2519215C2/ru active
- 2008-11-03 CN CN200880113724XA patent/CN101878028A/zh active Pending
- 2008-11-03 EP EP08845122.4A patent/EP2299998B1/en not_active Not-in-force
- 2008-11-03 BR BRPI0818310A patent/BRPI0818310A8/pt not_active IP Right Cessation
-
2010
- 2010-04-26 IL IL205362A patent/IL205362A/en active IP Right Grant
- 2010-04-30 ZA ZA2010/03030A patent/ZA201003030B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011502174A (ja) | 2011-01-20 |
| EP2299998A1 (en) | 2011-03-30 |
| CA2704286A1 (en) | 2009-05-07 |
| US20100286269A1 (en) | 2010-11-11 |
| MX338513B (es) | 2016-04-20 |
| PT2299998T (pt) | 2018-04-02 |
| WO2009055933A1 (en) | 2009-05-07 |
| ES2664594T3 (es) | 2018-04-20 |
| DK2299998T3 (en) | 2018-03-26 |
| IL205362A0 (en) | 2010-12-30 |
| US9532962B2 (en) | 2017-01-03 |
| BRPI0818310A2 (pt) | 2017-10-10 |
| MX2010004856A (es) | 2010-06-30 |
| RU2519215C2 (ru) | 2014-06-10 |
| IL205362A (en) | 2015-01-29 |
| RU2010122302A (ru) | 2011-12-10 |
| NO2299998T3 (enExample) | 2018-06-02 |
| KR101601987B1 (ko) | 2016-03-09 |
| EP2299998B1 (en) | 2018-01-03 |
| ZA201003030B (en) | 2011-02-23 |
| JP5575655B2 (ja) | 2014-08-20 |
| EP2299998A4 (en) | 2011-03-30 |
| AU2008318196A1 (en) | 2009-05-07 |
| CA2704286C (en) | 2016-08-23 |
| KR20100106958A (ko) | 2010-10-04 |
| MY151439A (en) | 2014-05-30 |
| NZ584981A (en) | 2012-05-25 |
| AU2008318196B2 (en) | 2014-04-10 |
| CN101878028A (zh) | 2010-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818310A8 (pt) | Glicerídeos e ácidos graxos de cadeia média como agentes nefroprotetores | |
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| CL2015003022A1 (es) | Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica | |
| CL2012002317A1 (es) | Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras. | |
| CL2009000048A1 (es) | Uso de compuestos derivados de triterpenoides en el tratamiento de insuficiencia renal, y enfermedades asociadas tales como: nefropatías, resistencia a la insulina, diabetes, patologías vasculares, entre otras. | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| CL2012000215A1 (es) | Composicion farmaceutica que comprende un fucano en combinacion con por lo menos un excipiente, relleno, portador o diluyente; kit que la comprende; y uso para inhibir, prevenir o tratar una enfermedad proliferativa o inflamatoria tal como una adhesion fibrosa, peritonitis, isquemia y rosacea, entre otras. | |
| CL2012000333A1 (es) | Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico. | |
| PE20120371A1 (es) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak | |
| MX2013007189A (es) | Metodos y composiciones adecuados para manejar glucosa en sangre en animales. | |
| EA201391315A1 (ru) | Гуанидиновое соединение | |
| WO2013180834A3 (en) | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria | |
| WO2012019188A3 (en) | Methods and compositions for the inhibition of fructokinase | |
| USD678911S1 (en) | Water pump adapter | |
| CL2012002437A1 (es) | Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos. | |
| CL2013001411A1 (es) | Peptido que posee actividad antiapoptotica; conjugado que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o condicion asociada con apoptosis en un sujeto. | |
| HK1214552A1 (zh) | 在腎損傷的受試者中用泊馬度胺治療癌症 | |
| BR112022003745A2 (pt) | Proteínas de fusão terapêuticas | |
| EP3980017A4 (en) | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality | |
| GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| BR112019005224A2 (pt) | forma de dosagem para alívio prolongado | |
| DK2175877T3 (da) | Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme | |
| BRPI0913839A2 (pt) | composição farmacêutica com glicosaminoglicanos e uso da mesma no tratamento de úlceras crônicas | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PROMETIC PHARMA SMT LIMITED (CA) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2747 DE 29-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |